KR20240077305A - Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease containing pterocarpan-based compound - Google Patents

Abstract

According to the present invention, it was confirmed that the pterocarpan-based compound not only suppresses NO production, inflammation-related cytokines, and chemokine expression in alveolar macrophages, but also suppresses the deterioration of lung function and lung tissue collapse caused by emphysema. It has been done. Therefore, the pharmaceutical composition of the present invention can be usefully used as a preventive or therapeutic agent for emphysema, a major lesion of chronic obstructive pulmonary disease.

Description

Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease containing pterocarpan-based compound {Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease containing pterocarpan-based compound}

The present invention relates to a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease containing a pterocarpan-based compound.

Emphysema is one of the chronic obstructive pulmonary diseases (COPD), in which the walls of the inter-alveolar spaces in the terminal bronchioles lose elasticity and are destroyed, causing abnormal and permanent expansion, which reduces the lung's oxygen-carbon dioxide exchange capacity. It is a disease that makes breathing difficult.

In addition, in emphysema, the alveolar alveoli that make up the lungs are destroyed, reducing the surface area in contact with oxygen and reducing the elasticity of the lungs, causing permanent airway obstruction. As the alveolar walls themselves are destroyed and shrunk due to inflammation, their inherent elasticity is reduced. As a result, the elastic modulus of the lungs is lowered and the airways narrow as they contract, causing symptoms of shortness of breath.

The main cause of emphysema is smoking. It is known that the risk of developing the disease increases as the amount of smoking increases. Since lung vital capacity decreases more severely than the normal decrease with age, long-term smoking destroys normal lung tissue and causes changes in emphysema. Additionally, the more you smoke, the more your lung capacity decreases, and symptoms such as shortness of breath may appear early. In addition, reduced expression of alpha-1 antitrypsin (α1-antitrypsin), which inhibits proteolytic enzymes, is also known to be a cause of emphysema. However, the etiologies known to date do not sufficiently explain the characteristics of emphysema, so research on mechanisms by other factors is necessary.

There are also insufficient medicines and treatment methods to treat emphysema. Because emphysema is difficult to treat fundamentally because the alveoli are physically damaged and do not regenerate, the treatments currently used are only symptomatic treatments based on symptoms, such as steroids to relieve inflammatory reactions, bronchodilators to relieve shortness of breath, and expectorants. do. To date, the ultimate cure has not been achieved and only conservative treatment is available, and the fatality rate is very high.

Meanwhile, Pterocarpans is a derivative of isoflavonoids found in the Fabaceae family, consisting of C-4-carbonyl and C- of 2'-hydroxyisoflavanones. It is characterized by comprising a fused furan ring structure arising from ring closure between the 2'-positions (C-2'-positions). Flavonoids are used for the prevention or treatment of various diseases due to their various physiological activities, but there has been no report on whether they are effective as a prevention or treatment for emphysema.

(Korea Open Patent) No. 10-2015-0009448 (2015.01.26.)

One object of the present invention is to provide a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, which contains a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition for preventing or improving chronic obstructive pulmonary disease containing a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Another object of the present invention is to provide a health functional food composition for preventing or improving chronic obstructive pulmonary disease containing a pterocarpan-based compound or a foodologically acceptable salt thereof as an active ingredient.

However, the technical problem to be achieved by the present invention is not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art to which the present invention belongs from the description below. There will be.

The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.

In one embodiment of the present invention, the compound may include a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof. However, it is not limited to this.

In one embodiment of the present invention, the chronic obstructive pulmonary disease may be emphysema, but is not limited thereto.

In one embodiment of the present invention, the composition may exhibit anti-inflammatory activity of one or more of the following, but is not limited thereto:

Inhibition of NO production by alveolar macrophages; and

Inhibiting the expression of one or more cytokines or chemokines selected from the group consisting of TNF-α, IL-1β, and IL-6.

In one embodiment of the present invention, the composition may exhibit one or more of the following activities, but is not limited thereto:

Suppresses the effects of reduced lung function caused by emphysema; and

Inhibits the effects of lung tissue breakdown caused by emphysema.

In one embodiment of the present invention, the composition may be administered orally, but is not limited thereto.

The present invention provides a quasi-drug composition for preventing or improving chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.

In one embodiment of the present invention, the compound may include a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof. However, it is not limited to this.

In one embodiment of the present invention, the chronic obstructive pulmonary disease may be emphysema, but is not limited thereto.

The present invention provides a health functional food composition for preventing or improving chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a foodologically acceptable salt thereof as an active ingredient.

In one embodiment of the present invention, the compound may include a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a foodologically acceptable salt thereof. However, it is not limited to this.

In one embodiment of the present invention, the chronic obstructive pulmonary disease may be emphysema, but is not limited thereto.

In addition, the present invention provides the prevention and improvement of chronic obstructive pulmonary disease or emphysema, comprising administering a composition containing a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof. Or provide a treatment method.

Additionally, the present invention provides the use of a composition containing a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient to prevent, improve, or treat chronic obstructive pulmonary disease or emphysema.

In addition, the present invention provides the use of a composition containing a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient for producing a preventive, ameliorating or therapeutic agent for chronic obstructive pulmonary disease or emphysema.

In addition, the present invention provides a step of administering a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof to a subject in need thereof. Provides a method for preventing, improving, or treating chronic obstructive pulmonary disease, or emphysema, including.

In addition, the present invention relates to the prevention of chronic obstructive pulmonary disease or emphysema by a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof. Provides remedial or therapeutic use.

In addition, the present invention provides neolautenol, shinpterocarpin, and cristacarpin, or pharmaceutically acceptable salts thereof, for the production of agents for preventing, improving, or treating chronic obstructive pulmonary disease or emphysema. Provided is a use of a compound selected from the group consisting of:

According to the present invention, it was confirmed that the pterocarpan-based compound not only suppresses NO production, inflammation-related cytokines, and chemokine expression in alveolar macrophages, but also suppresses the deterioration of lung function and lung tissue collapse caused by emphysema. It has been done. Therefore, the pharmaceutical composition of the present invention is effective in treating emphysema, the main lesion of chronic obstructive pulmonary disease. It can be useful as prevention or treatment.

Figures 1A, 1B, and 1C are graphs showing the results of experiments confirming cytotoxicity by neolautenol (Neo), synterocarpine (Shin), and cristacarpine (Crista).
Figure 2 is a graph showing the inhibitory effect of terocarphane compounds, neolautenol (Neo), synterocarpine (Shin), and cristacarpine (Crista) on NO production in alveolar macrophages induced by LPS.
Figures 3a to 3c are graphs showing the inhibitory effect of terocarphane-based compounds on the expression of inflammatory cytokines and chemokines in alveolar macrophages induced by LPS, wherein Figure 3a is neolautenol (Neo) and Figure 3b is Neolautenol (Neo). Terocarpine (Shin), and Figure 3C shows the inhibitory effect of cristacarpine (Crista).
Figure 4 is a graph showing the effect of improving lung function by a terocarphane-based compound in an elastase (PPE)-induced emphysema mouse model.
Figures 5 and 6 are photographs and graphs showing the effect of suppressing lung tissue collapse by a terocarpane-based compound in an elastase (PPE)-induced emphysema mouse model.

The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Pterocarpan of the present invention is a derivative of isoflavonoids found in the Fabaceae family, and is composed of C-4-carbonyl and C of 2'-hydroxyisoflavanones. It may be characterized as including, but is not limited to, a fused furan ring structure arising from ring closure between the -2'-positions (C-2'-positions).

Terocarpan of the present invention may have the following structural formula as a basis, but is not limited thereto.

Terocarphane may contain a 1-benzofuran moiety (blue dotted circle) fused to the 2H-chromene moiety (green dotted circle) shown in the structural formula above, and its systematic name is 6H- It may be named [1]benzofuro[3,2-c]chromene (6H-[1]benzofuro[3,2-c]chromene), but is not limited thereto. Additionally, new numbering of moieties may be indicated by red numbers.

In one embodiment of the present invention, the compound may be selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof.

In the present invention, any one or more compounds belonging to the terocarpane family of compounds may exhibit anti-inflammatory activity, but according to one embodiment of the present invention, the three compounds are excellent in preventing chronic obstructive pulmonary disease including emphysema. , in that the improvement or treatment effect has been proven, the effect of preventing, improving, or treating chronic obstructive pulmonary disease, including emphysema, may be particularly significantly superior.

It was confirmed that the terocarpane-based compounds according to the present invention, especially neolautenol, synteropakin, and cristacapine, each exhibit anti-inflammatory effects. In particular, among a wide range of diseases caused by inflammation, the three types of terocarpane-based compounds according to the present invention are useful in preventing, improving, or treating emphysema, as they exhibit remarkable activity in suppressing the decline in lung function and lung tissue collapse caused by emphysema. It was confirmed that it could be used.

In addition, each compound has been confirmed to have excellent effects even as a single ingredient, and it is obvious in the art that a combination of two or more of each compound is expected to produce a synergy effect to some extent. Therefore, the present invention may include a combination of the above two or more.

Neolautenol is a natural compound belonging to the phytoalexin group and is known to have anticancer effects on various cancer types. For example, neolautenol has been shown to have strong inhibitory activity against cancer cells, including MDA-MB-231 breast cancer cells, and can be used to prevent colon cancer, but is not limited to this. Additionally, neolautenol has been shown to exhibit antibacterial activity against Gram-positive bacteria such as Staphylococcus aureus, which is resistant to antibiotics, but is not limited to this.

Neolautenol of the present invention may be expressed by the following structural formula, but is not limited thereto.

Synterocarpines are benzo-pyrano-furano-benzene compounds containing a 6H-[1]benzofuro[3,2-c]chromene skeleton and may belong to a class of organic compounds known as pterocarpans. Although isoflavonoids are derivatives of (-)-Shinpterocarpin, they can be found in many different foods, such as, but not limited to, herbs and spices, green tea, herbal tea, and black tea.

Synterocarpine of the present invention can be expressed by the following structural formula, but is not limited thereto.

Chrystakapine is a phenolic compound found in the herb Erythrina burana. Cristacarpin may exhibit moderate but selective activity against, but is not limited to, yeast mutants deficient in DNA repair.

The cristacarpine of the present invention can be expressed by the following structural formula, but is not limited thereto.

In the present invention, neolautenol, shinpterocarpin, and cristacarpin or pharmaceutically acceptable salts thereof may be derived from natural products or may be synthetic compounds, but are not limited thereto. .

In addition, in the present invention, neolautenol, shinpterocarpin, and cristacarpin may have structural formulas known for each substance, for example, the structural formulas presented in the present invention, but are not limited thereto. No, it may include a pharmaceutically acceptable salt thereof. In addition, it can collectively refer to the widest range of compounds, including all compounds that exhibit the same activity as each of the above compounds or that can be generally judged to be the same in the art.

The scope of the compound according to the present invention may also include pharmaceutically acceptable salts thereof, and in the present invention, the term “pharmaceutically acceptable salt” includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases. do.

As used herein, the term “pharmaceutically acceptable” means that the benefit/risk ratio is reasonable for use in contact with tissue of a subject (e.g., human) without undue toxicity, irritation, allergic reaction, or other problems or complications. It refers to a compound that is suitable and within the scope of sound medical judgment. The pharmaceutically acceptable salts include, for example, acid addition salts formed by pharmaceutically acceptable free acids and pharmaceutically acceptable metal salts.

Specifically, examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methane sulfuric acid. Fonic acid, formic acid, benzoic acid, malonic acid, gluconic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, etc. can be mentioned. Acid addition salts can be prepared by conventional methods, for example, by dissolving the compound in an excessive amount of aqueous acid and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone, or acetonitrile. It can also be prepared by heating equimolar amounts of the compound and an acid or alcohol in water and then evaporating the mixture to dryness, or suction filtering the precipitated salt.

Salts derived from suitable bases may include, but are not limited to, alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium. The alkali metal or alkaline earth metal salt can be obtained, for example, by dissolving the compound in an excessive amount of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. At this time, it is particularly pharmaceutically suitable to prepare sodium, potassium or calcium salts as metal salts, and the corresponding silver salts can be obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (eg, silver nitrate).

The scope of the compound of the present invention may include not only pharmaceutically acceptable salts, but also all isomers, hydrates, and solvates that can be prepared by conventional methods.

The compounds may have non-aromatic double bonds and one or more asymmetric centers. Accordingly, they may occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans-isomers. All these isomeric forms are considered.

In addition, the scope of the compound according to the present invention may include biological functional equivalents having mutations in the amino acid sequence that exhibit equivalent biological activity to the compound of the present invention. These amino acid sequence variations can be made based on the relative similarity of amino acid side chain substitutions, such as hydrophobicity, hydrophilicity, charge, and size. By analysis of the size, shape and type of amino acid side chain substitutions, alanine and glycine have similar sizes; Lysine is a positively charged residue; It can be seen that glutamine and threonine are not charged. Therefore, based on these considerations, alanine and glycine; And glutamine and threonine can be said to be biologically equivalent in function. Unless otherwise stated, the amino acid sequences disclosed herein are, in principle, written in order from the N terminus to the C terminus.

In introducing mutations, the hydrophobic index of the amino acid can be considered. Each amino acid is assigned a hydrophobicity index based on its hydrophobicity and charge: isoleucine (+4.5); Valine (+4.2); leucine (+3.8); Phenylalanine (+2.8); Cysteine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); histidine (-3.2); glutamic acid (-3.5); Glutamine (-3.5); Aspartic acid (-3.5); Asparagine (-3.5); Lysine (-3.9); and arginine (-4.5).

The hydrophobic amino acid index is very important in imparting interactive biological functions to proteins. It is a known fact that similar biological activity can be maintained only when substituted with an amino acid having a similar hydrophobicity index. When introducing a mutation with reference to the hydrophobicity index, substitution is made between amino acids showing a difference in the hydrophobicity index, preferably within ±2, more preferably within ±1, and even more preferably within ±0.5.

Meanwhile, it is also well known that substitution between amino acids with similar hydrophilicity values results in proteins with equal biological activity. As disclosed in U.S. Patent No. 4,554,101, the following hydrophilicity values are assigned to each amino acid residue: arginine (+3.0); Lysine (+3.0); Aspartic acid (+3.0±1); glutamic acid (+3.0±1); serine (+0.3); Asparagine (+0.2); Glutamine (+0.2); Glycine (0); Threonine (-0.4); Proline (-0.5±1); Alanine (-0.5); histidine (-0.5); Cysteine (-1.0); Methionine (-1.3); Valine (-1.5); Leucine (-1.8); Isoleucine (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5); Tryptophan (-3.4).

When introducing a mutation with reference to the hydrophilicity value, substitution is made between amino acids showing a difference in hydrophilicity value, preferably within ±2, more preferably within ±1, and even more preferably within ±0.5.

Amino acid exchanges in proteins that do not overall alter the activity of the molecule are known in the art (H. Neurath, R.L. Hill, The Proteins, Academic Press, New York, 1979). The most commonly occurring exchanges are amino acid residues Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/ It is an exchange between Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.

Considering the mutations with bioequivalent activity described above, the oligopeptide is not limited to its amino acid sequence (AQTGTGKT), but is interpreted to also include sequences showing substantial identity thereto. The above substantial identity can be achieved by aligning the sequence of the present invention and any other sequence to correspond as much as possible, and analyzing the aligned sequence using an algorithm commonly used in the art. It means a sequence showing 62.5% homology, more preferably 75% or more homology, and most preferably 87.5% or more homology. Alignment methods for sequence comparison are known in the art.

In one embodiment of the present invention, the chronic obstructive pulmonary disease may be emphysema, but is not limited thereto.

In the present invention, the chronic obstructive pulmonary disease may include any one or more selected from the group consisting of chronic obstructive bronchitis, chronic bronchiolitis, chronic bronchitis, chronic asthma, and emphysema. there is.

In the present invention, chronic bronchitis is a case where there is a chronic cough accompanied by sputum for at least 2 consecutive years and 3 months or more per year without a specific cause (respiratory or cardiac disease) causing chronic cough. Simple chronic bronchitis may mean hypersecretion of bronchial secretions but no airflow obstruction. Chronic obstructive bronchitis (chronic obstructive bronchitis): A small number of patients with simple chronic bronchitis develop irreversible narrowing of the small airways and develop chronic obstructive bronchitis, in which bronchioles less than 2 mm in diameter are blocked by mucus. Symptoms of decreased cross-sectional area of small airways may occur due to plugging, goblet cell metaplasia, inflammation, increase in smooth muscle, and fibrosis.

In the present invention, emphysema is an abnormal permanent expansion of the alveolar space (airspace) distal to the terminal bronchioles, and may refer to a case accompanied by destruction of the alveolar space wall but without pulmonary fibrosis, but is not limited thereto. .

Emphysema can be classified into centrilobular emphysema, panlobular emphysema, and distal acinar emphysema.

First, lobular emphysema or proximal emphysema begins as a lesion in the respiratory bronchiole and spreads to the periphery. It occurs in association with long-term smoking and occurs in the upper lobes of the lung. Focal emphysema is a form of lobular emphysema that occurs in coal miners' pneumoconiosis.

Second, panlobular emphysema affects all alveoli equally and is prevalent in the lower lobes of the lung. This form of emphysema occurs mainly in homozygous alpha1-antitrypsin deficiency.

Third, primary or paraseptal emphysema invades the distal airways of the alveolar ducts and alveolar sacs. The lesions are distributed around the fibrous septum or pleura, and apical bullae may rupture, causing a spontaneous pneumothorax, or giant bubbles may cause compression of the surrounding normal lung. In this form of emphysema, airflow remains normal.

In one embodiment of the present invention, the composition may exhibit anti-inflammatory activity of one or more of the following, but is not limited thereto:

Inhibition of NO production by alveolar macrophages; and

Inhibiting the expression of one or more cytokines or chemokines selected from the group consisting of TNF-α, IL-1β, and IL-6.

In one embodiment of the present invention, the composition may exhibit one or more of the following activities, but is not limited thereto:

Suppresses the effects of reduced lung function caused by emphysema; and

Inhibits the effects of lung tissue breakdown caused by emphysema.

In one embodiment of the present invention, the composition may be administered orally, but is not limited thereto.

The “pharmaceutical composition” according to the present invention may further include appropriate carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions. The excipient may be, for example, one or more selected from the group consisting of diluents, binders, disintegrants, lubricants, adsorbents, humectants, film-coating materials, and controlled-release additives.

The pharmaceutical composition according to the present invention can be prepared as powder, granules, sustained-release granules, enteric-coated granules, solutions, eye drops, ellipsis, emulsions, suspensions, spirits, troches, perfumes, and limonadese according to conventional methods. , tablets, sustained-release tablets, enteric-coated tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric-coated capsules, pills, tinctures, soft extracts, dry extracts, liquid extracts, injections, capsules, perfusate, It can be formulated and used in the form of external preparations such as warning agents, lotions, pasta preparations, sprays, inhalants, patches, sterilized injection solutions, or aerosols, and the external preparations include creams, gels, patches, sprays, ointments, and warning agents. , it may have a dosage form such as lotion, liniment, pasta, or cataplasma.

Carriers, excipients, and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, and calcium. These include phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Additives to tablets, powders, granules, capsules, pills, and troches according to the present invention include corn starch, potato starch, wheat starch, lactose, white sugar, glucose, fructose, di-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, and phosphoric acid. Calcium monohydrogen, calcium sulfate, sodium chloride, sodium bicarbonate, purified lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropylmethyl. Excipients such as cellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate, and Primogel; Gelatin, gum arabic, ethanol, agar powder, cellulose acetate phthalate, carboxymethyl cellulose, calcium carboxymethyl cellulose, glucose, purified water, sodium caseinate, glycerin, stearic acid, sodium carboxymethyl cellulose, sodium methyl cellulose, methyl cellulose, microcrystalline cellulose, dextrin. , hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, refined shellac, starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc. binders can be used, Hydroxypropyl methyl cellulose, corn starch, agar powder, methyl cellulose, bentonite, hydroxypropyl starch, sodium carboxymethyl cellulose, sodium alginate, calcium carboxymethyl cellulose, calcium citrate, sodium lauryl sulfate, silicic anhydride, 1-hydroxy Propylcellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, Disintegrants such as amylopectin, pectin, sodium polyphosphate, ethyl cellulose, white sugar, magnesium aluminum silicate, di-sorbitol solution, light anhydrous silicic acid; Calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium, kaolin, petrolatum, sodium stearate, cocoa fat, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, 6000, liquid paraffin, hydrogenated soybean oil (Lubri) wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, Macrogol, synthetic aluminum silicate, silicic anhydride, higher fatty acids, higher alcohol, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, Lubricants such as sodium acetate, sodium oleate, dl-leucine, and light anhydrous silicic acid may be used.

Additives to the liquid according to the present invention include water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitol fatty acid esters (twin esters), polyoxyethylene monoalkyl ethers, lanolin ethers, Lanolin esters, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, etc. can be used.

A solution of white sugar, other sugars, or sweeteners, etc. may be used in the syrup according to the present invention, and if necessary, flavoring agents, colorants, preservatives, stabilizers, suspending agents, emulsifiers, thickening agents, etc. may be used.

Purified water can be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. can be used as needed.

The suspension according to the present invention may include acacia, tragacantha, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, and HPMC 2910. Surfactants, preservatives, stabilizers, colorants, and fragrances may be used as needed.

Injections according to the present invention include distilled water for injection, 0.9% sodium chloride injection, IV solution, dextrose injection, dextrose + sodium chloride injection, PEG, lactated IV solution, ethanol, propylene glycol, non-volatile oil - sesame oil. , solvents such as cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristic acid, and benzene benzoate; Solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, Tween, nicotinic acid amide, hexamine, and dimethylacetamide; Buffering agents such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums; Isotonic agents such as sodium chloride; Stabilizers such as sodium bisulfite (NaHSO ₃ ) carbon dioxide gas, sodium metabisulfite (Na ₂ S ₂ O ₅ ), sodium sulfite (Na ₂ SO ₃ ), nitrogen gas (N ₂ ), and ethylenediaminetetraacetic acid; Sulfurizing agents such as sodium bisulfide 0.1%, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetate, and acetone sodium bisulfite; Analgesics such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; It may contain suspending agents such as CM sodium, sodium alginate, Tween 80, and aluminum monostearate.

Suppositories according to the present invention include cacao oil, lanolin, witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cacao butter + Cholesterol, lecithin, Lanet wax, glycerol monostearate, Tween or Span, Imhausen, monolene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego -G), Cebes Pharma 16, Hexalide Base 95, Cotomar, Hydrocote SP, S-70-XXA, S-70-XX75(S-70-XX95), Hydro Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Massaupol, Masupol-15, Neosupostal-N, Paramound-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), suppositories type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wecobi (W, R, S, M, Fs), Tegestor triglyceride base (TG-95, MA, 57) and The same mechanism can be used.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract with at least one excipient, such as starch, calcium carbonate, and sucrose. ) or prepared by mixing lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium styrate talc are also used.

Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, activity of the drug, and the type and severity of the patient's disease. It can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field.

The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art to which the present invention pertains.

The pharmaceutical composition of the present invention can be administered to an individual through various routes. All modes of administration are contemplated, including oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal space (intrathecal) injection, sublingual administration, buccal administration, intrarectal injection, vaginal injection. It can be administered by internal insertion, ocular administration, otic administration, nasal administration, inhalation, spraying through the mouth or nose, dermal administration, transdermal administration, etc.

The pharmaceutical composition of the present invention is determined depending on the type of drug as the active ingredient along with various related factors such as the disease to be treated, the route of administration, the patient's age, gender, weight, and severity of the disease. Specifically, the effective amount of the composition according to the present invention may vary depending on the patient's age, gender, and weight, and is generally administered at 0.001 to 150 mg, preferably 0.01 to 100 mg, per kg of body weight every day or every other day, or 1 It can be administered in divided doses 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, severity of disease, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

The present invention provides a quasi-drug composition for preventing or improving chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.

In one embodiment of the present invention, the compound may be selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or pharmaceutically acceptable salts thereof. Any one or more compounds belonging to the carpane family of compounds may exhibit anti-inflammatory or preventive, ameliorating or therapeutic effects on chronic obstructive pulmonary disease, including emphysema, but the preventive, ameliorating or therapeutic effects of the above three compounds may be particularly significantly superior. You can.

In one embodiment of the present invention, the chronic obstructive pulmonary disease may be emphysema, but is not limited thereto.

In this specification, the term “quasi-drug” refers to a preparation used for sterilization, insecticide, and similar purposes to prevent infectious diseases as described in Article 2, Paragraph 7, C, of the Pharmaceutical Affairs Act, and is used to diagnose, treat, improve, alleviate, and treat human or animal diseases. Alternatively, it may refer to products used for preventive purposes that have a milder effect than pharmaceuticals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are excluding articles used for medicinal purposes, such as textile and rubber products used for the treatment or prevention of diseases in humans and animals, those that have a minor or no direct effect on the human body, and those that are used as instruments or machines. This includes things that are not and similar products, as well as sterilizers and pesticides to prevent infectious diseases.

Additionally, the quasi-drugs may include external skin preparations and personal hygiene products.

The skin may include, but is not limited to, all skin areas of the body, including the face, hands, arms, legs, feet, chest, stomach, back, buttocks, and scalp.

The type or formulation of the quasi-drug composition of the present invention is not particularly limited, but may be a bandage, gauze, cotton wool, bandage, disinfectant cleaner, shower foam, gargle, wet tissue, detergent soap, hand wash, humidifier filler, mask, or filter filler. there is.

When the composition of the present invention is included in a quasi-drug for the purpose of improving skin condition, the composition can be used as is or together with other quasi-drug ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use, and the quasi-drug composition according to the present invention may contain 0.01% to 20% by weight of microorganisms, their lysates, cultures, or mixtures thereof based on the total weight of the composition. there is.

The external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, lotion, or a combination thereof. The skin external preparations include ingredients commonly used in skin external preparations such as cosmetics and medicines, such as water-based ingredients, oil-based ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, or a combination thereof may be appropriately mixed according to need. The skin external preparations include metal sequestrants such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belafamil, licorice extract, glablidin, and calin. Hot water extract of fruit, various herbal medicines, drugs such as tocopherol acetate, glytylitinic acid, tranexamic acid and its derivatives or salts, vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, kojic acid, glucose, fructose, Sugars such as trehalose can also be appropriately mixed.

The composition for external application for skin according to the present invention may contain 0.00001% to 80% by weight of microorganisms, their lysates, cultures, or mixtures thereof based on the total weight of the composition, but is not limited thereto, and the addition of the above weight%, etc. The content and types of added substances may include all amounts, mixing ratios, and substances commonly added in the art.

In the present invention, “individual” refers to a subject in need of treatment for a disease, and more specifically, human or non-human primates, mice, rats, dogs, cats, horses, cows, etc. refers to mammals of

In the present invention, “administration” means providing a given composition of the present invention to an individual by any appropriate method. In the present invention, “prevention” refers to any action that suppresses or delays the onset of the desired disease, and “treatment” refers to the improvement or improvement of the desired disease and its associated metabolic abnormalities by administration of the pharmaceutical composition according to the present invention. It refers to all actions that are beneficially changed, and “improvement” refers to all actions that reduce parameters related to the target disease, such as the degree of symptoms, by administering the composition according to the present invention.

The present invention provides a health functional food composition for preventing or improving chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a foodologically acceptable salt thereof as an active ingredient.

In one embodiment of the present invention, the compound may be selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a foodologically acceptable salt thereof. Any one or more compounds belonging to the carpane family of compounds may exhibit anti-inflammatory or preventive, ameliorating or therapeutic effects on chronic obstructive pulmonary disease, including emphysema, but the preventive, ameliorating or therapeutic effects of the above three compounds may be particularly significantly superior. You can.

In one embodiment of the present invention, the chronic obstructive pulmonary disease may be emphysema, but is not limited thereto.

In the present invention, the term “foodologically acceptable salt” includes salts derived from foodologically acceptable organic acids, inorganic acids, or bases.

The health functional food of the present invention may include health food.

In the present invention, food refers to a natural product or processed product containing one or more nutrients, and preferably means that it has undergone a certain degree of processing to become directly edible. In the usual sense, It includes all health functional foods, beverages, food additives, and beverage additives.

In the present invention, the functional food (functional food) is the same term as food for special health use (FoSHU), and is a medicine processed to efficiently exhibit bioregulatory functions in addition to nutritional supply, and medical effects. It refers to a food with high phosphorus and can be manufactured in tablet, capsule, pill, granule, powder, liquid, flake, paste, syrup, gel, jelly, bar, or film formulations. Here, “functionality” means controlling nutrients for the structure and function of the human body or obtaining useful effects for health purposes, such as physiological effects.

In the present invention, there is no particular limitation on the type of health functional food. Specifically, examples of foods to which the composition of the present invention can be added include dairy products including ice cream, various soups, beverages, teas, drinks, alcoholic beverages, and vitamin complexes, and in particular, the function of the food in the conventional sense. It includes all foods designed to sufficiently express in the living body the body's regulatory functions related to biological defense rhythm regulation, disease prevention and recovery, etc., which are included in food groups or food compositions that have been given added value to function and express for a specific purpose.

A terocarpane-based compound according to an embodiment of the present invention, or any one selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin, or food-acceptable salts thereof. Health food and health functional food compositions containing compounds (hereinafter referred to as active substances) as active ingredients can be added to food as is or used together with other foods or food ingredients, and can be used appropriately according to general methods. Additionally, the mixing amount of the active substance can be appropriately determined depending on the purpose of use (for example, prevention or improvement). In general, the amount of the above composition in health foods and health functional foods may be added in the range of 0.1 to 90 parts by weight of the total weight of the food. However, in the case of long-term intake for the purpose of maintaining or controlling health, the amount may be below the above range, and from the viewpoint of safety, the active ingredient according to the present invention may be used in an amount above the above range.

Health food and health functional food compositions containing the active ingredient according to the present invention have no particular restrictions other than containing the active ingredient of the present invention as an essential ingredient in the indicated ratio, and, like ordinary beverages, various flavoring agents or Natural carbohydrates, etc. may be included as additional ingredients. Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. The ratio of natural carbohydrates may generally be about 1 to 20 parts by weight, preferably about 5 to 12 parts by weight, per 100 parts by weight of the health functional food composition of the present invention, but is not limited thereto.

In addition to the above, health food and health functional food compositions containing the active substances of the present invention include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants, and thickening agents (cheese, chocolate, etc.) ), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. may be included. In addition, the health food and health functional food composition of the present invention may include natural fruit juice and pulp for producing fruit juice drinks and vegetable drinks.

These ingredients can be used independently or in combination, and are generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health food and health functional food composition containing the active substance of the present invention, but are not limited thereto. .

In the present invention, “food additives” refer to substances used by adding, mixing, infiltrating, or other methods into food when manufacturing, processing, or preserving food. When taken over a long period of time, such as health functional foods, “food additives” refer to substances that are used in food production, processing, or preservation. Must be harmless to

When using the composition of the present invention as a food additive, the food additive can be added as is to the composition of the present invention or used together with other foods or food ingredients, and can be used appropriately according to conventional methods.

The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). In general, when producing food or beverages, the composition of the present invention may be added in an amount of 15% by weight or less, or 10% by weight or less, based on the raw materials. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

In the present invention, the composition may include various food auxiliary additives that are foodologically acceptable, and may further include appropriate carriers, excipients, and diluents commonly used in the production of foods.

In addition, in addition to the above, the composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain carbonating agents used in alcohol and carbonated drinks. In addition, the composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01-0.20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto and can be adjusted at an optimal or arbitrary dosage depending on the type and function of the product being used. It can be.

In the present invention, there is no particular limitation on the type of food. Examples of foods to which the above substances can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, These include alcoholic beverages and vitamin complexes, and may include all health functional foods in the conventional sense, but are not limited thereto.

In addition, the composition according to the present invention can be added to health drinks, and can contain various flavoring agents or natural carbohydrates as additional ingredients like ordinary drinks. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate may generally be about 0.01-0.20g, or about 0.04-0.10g per 100 mL of the composition of the present invention, but is not limited thereto, and may be a common dose added in the art, or In order to improve the efficacy of the composition, the maximum range may be included, and an optimal, arbitrary dosage may be included considering the synergistic effect with other substances added together.

Below, preferred embodiments are presented to aid understanding of the present invention. However, the following examples are provided only to make the present invention easier to understand, and the content of the present invention is not limited by the following examples.

[Example]

Example 1. Confirmation of cytotoxicity of terocarpane-based compounds

MTT assay was performed to confirm the toxicity of pterocarpan-based compounds to normal cells. Specifically, the toxicity of neolautenol (Neo), shinpterocarpin (Shin), and cristacarpin (Crista) to mouse lung epithelial cells, MLE-12, or mouse-derived hippocampal cells, HT-22. was evaluated by MTT assay.

As a result, as shown in Figures 1a, 1b, and 1c, 10 and 20 μΜ of neolautenol, 0, 20, and 50 μM of synterocarpine, and 1, 5, and 10 μM of cristacarpine were treated, respectively. It was confirmed that the viability of the cells was more than 50% compared to the control group, showing low toxicity to normal cells.

Example 2. Confirmation of anti-inflammatory effect of terocarpane-based compounds

To confirm the anti-inflammatory effect of terocarphane compounds, the inhibitory effect on NO production in mouse-derived alveolar macrophages was analyzed. Specifically, the terocarphane compounds neolautenol (10 and 20 μM), shinpterocarpin (50 μM), and cristacarpin (1, and After treatment with 5 μM) and LPS (0.5 μg/mL) for 20 hours, the NO released in the medium was evaluated by converting it to nitrite concentration.

As a result, as shown in Figure 2, neolautenol, synterocarpine, and cristacarpine each significantly inhibited NO production by LPS.

Example 3. Confirmation of the effect of terocarpane-based compounds on suppressing inflammation-related cytokine expression

To confirm the anti-inflammatory effect of terocarphane-based compounds, the inhibitory effect on inflammation-related cytokine expression in mouse-derived alveolar macrophages was analyzed. Specifically, the mouse-derived alveolar macrophage cell line was treated with terocarphane-based compounds neolautenol (50 μM), synterocarpine (50 μM), and cristacapine (1, 5 μM) and LPS (0.5 μg/mL) for 20 hours. After processing, mRNA was isolated to confirm changes in expression of inflammatory cytokines, TNF-α, IL-1β, and IL-6.

As a result, as shown in Figures 3a to 3c, neolautenol, synterocarpine, and cristacarpine were confirmed to significantly inhibit the expression of inflammatory cytokines such as TNF-α, IL-1β, and IL-6, respectively. It has been done.

Example 4. Confirmation of the inhibitory activity of terocarpane-based compounds on the reduction of lung function caused by emphysema

The anti-inflammatory effect of terocarphane-based compounds in an emphysema-induced mouse model was confirmed through changes in lung function. Specifically, an emphysema mouse model was prepared by inducing emphysema in mice through respiratory administration of Elastase (0.25 U). Changes in lung function were analyzed after oral administration of neolautenol (25 mg/kg), synterocarpine (25 mg/kg), and cristacapine (10 mg/kg) to this emphysema mouse model.

As a result, as shown in Figure 4, pulmonary function abnormalities (increased compliance and decreased tissue elastance), which are typically seen in emphysema, were observed due to PPE treatment, but treatment with neolautenol, synterocarpine, and cristacarpine each occurred. It was confirmed that the above symptoms were significantly alleviated.

Example 5. Confirmation of the effect of terocarpane-based compounds on suppressing lung tissue collapse caused by emphysema

The anti-inflammatory effect of terocarphane-based compounds in an emphysema-induced mouse model was confirmed through changes in lung tissue breakdown. Specifically, with respect to the emphysema mouse model prepared in the same manner as in Example 4, lung tissue was removed from the mouse and changes in lung tissue were observed through H&E staining.

As a result, as shown in FIG. 5, collapse of lung tissue was confirmed due to PPE treatment, but it was confirmed that the collapse phenomenon was significantly reduced by treatment with neolautenol, synterocarpine, and cristacarpine, respectively.

In addition, as shown in Figure 6, as a result of quantifying lung tissue collapse due to emphysema using the Mean linear intercept, a significant effect of inhibiting lung tissue collapse by neolautenol, synterocarpine, and cristacapine was confirmed.

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims (12)

A pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.
According to paragraph 1,
The compound includes a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof, for preventing chronic obstructive pulmonary disease or Pharmaceutical composition for therapeutic use.
According to paragraph 1,
A pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, wherein the chronic obstructive pulmonary disease is emphysema.
According to paragraph 1,
A pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, wherein the composition exhibits anti-inflammatory activity of one or more of the following:
Inhibition of NO production by alveolar macrophages; and
Inhibiting the expression of one or more cytokines or chemokines selected from the group consisting of TNF-α, IL-1β, and IL-6.
According to paragraph 1,
A pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, wherein the composition exhibits one or more of the following activities:
Suppresses the effects of reduced lung function caused by emphysema; and
Inhibits the effects of lung tissue breakdown caused by emphysema.
According to paragraph 1,
The composition is a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, which is administered orally.
A quasi-drug composition for preventing or improving chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a pharmaceutically acceptable salt thereof as an active ingredient.
In clause 7,
The compound includes a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a pharmaceutically acceptable salt thereof, for preventing chronic obstructive pulmonary disease or Quasi-drug composition for improvement.
In clause 7,
A quasi-drug composition for preventing or improving chronic obstructive pulmonary disease, wherein the chronic obstructive pulmonary disease is emphysema.
A health functional food composition for preventing or improving chronic obstructive pulmonary disease, comprising a pterocarpan-based compound or a foodologically acceptable salt thereof as an active ingredient.
According to clause 10,
The compound includes a compound selected from the group consisting of neolautenol, shinpterocarpin, and cristacarpin or a food-acceptable salt thereof, for preventing chronic obstructive pulmonary disease or Health functional food composition for improvement.
According to clause 10,
A health functional food composition for preventing or improving chronic obstructive pulmonary disease, wherein the chronic obstructive pulmonary disease is emphysema.